Previous 10 | Next 10 |
Blueprint Medicines Corporation (BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Offic...
Blueprint Medicines press release (NASDAQ:BPMC): Q1 GAAP EPS of -$1.79 beats by $0.10. Revenue of $62.73M (+190.7% Y/Y) beats by $22.75M. For further details see: Blueprint Medicines GAAP EPS of -$1.79 beats by $0.10, revenue of $62.73M beats by $22.75M
Blueprint Medicines Reports First Quarter 2022 Results PR Newswire -- Achieved $23.8 million in AYVAKIT ® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway f...
Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.85 (-7.6% Y/Y) and the consensus Revenue Estimate is $39.98M (+85.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of...
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 PR Newswire CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conferenc...
Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...
Blueprint Medicines (NASDAQ:BPMC) on Friday announced a clinical trial supply agreement with AstraZeneca (AZN) under which it will evaluate its investigational agents BLU-945 and BLU-701 in combination with osimertinib in its ongoing SYMPHONY and HARMONY trials, respectively. Blueprint also a...
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer PR Newswire -- Early dose escalation data show dose-dependent reductions in ctDNA and tumor bur...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ): Food and Drug Admi...
The European Commission approved the expanded use of Blueprint Medicines' (NASDAQ:BPMC) Ayvakyt (avapritinib) as a monotherapy for adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least o...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...